Ryvu Therapeutics announces strategic reorganization to extend the cash runway for the development of RVU120 and the preclinical pipeline
Cash runway is extended from Q1 to H2 2026 with approximately €46 million (PLN 192 million) in cash and other financial assets held by Ryvu as of February 23, 2025.
manilatimes2h
Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit
Dr. Newman will deliver a scientific presentation on Tuesday, March 4, 2025, titled, "Employing Attenuated & Killed Gram-Negative Bacteria to Induce NK-Mediated Anti-Tumor Immunity.” In this ...
Boat Ultima Prime, Ultima Ember With Bluetooth Calling Support Launched in India: Price, Features
Boat Ultima Prime and the Ultima Ember smartwatches are both priced in India at Rs. 1,899, the company confirmed in a press ...